Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Kenvue (KVUE)

NYSE: KVUE · Personal Care Products · Summit, NJ

Our rating: Neutral

Call changed from Cautious to Neutral at $19.31, moderate conviction, October 30, 2026.

Breaks if: The neutral call turns positive if Kenvue reports organic revenue growth of at least 2% for two consecutive quarterly periods within the next four prints — that would signal the top-line trough has passed and justify the current multiple. It turns cautious if the year-on-year revenue decline deepens to 4% or worse in any single quarterly report, or if net margin compresses below 8.5% on a trailing twelve-month basis. Neither condition is true in the current filings.

Key figures

Market value$37.1B
Revenue, last 12 months$15.5B
Net income, last 12 months$1.7B
Free cash flow, last 12 months$2.3B
Price to earnings22.0×
Free cash flow yield6.3%
Dividend yield5.4%
Operating margin17.4%
Return on equity16.3%
Beta to the S&P 5000.19
Volatility, annualized29.0%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 27, 2026$3.9B3.2%$0.22$620M
June 28, 2026$4.0B3.0%$0.24$624M
March 29, 2026$3.9B4.5%$0.25$350M
December 28, 2025$3.8B3.2%$0.17$744M
September 28, 2025$3.8B−3.5%$0.21$196M
June 29, 2025$3.8B−4.0%$0.22$533M
March 30, 2025$3.7B−3.9%$0.17$249M
December 29, 2024$3.7B−0.1%$0.16$661M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

9 ledger entries and 22 corporate events on record. Share price as of November 6, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.